Published online Jun 28, 2020. doi: 10.35713/aic.v1.i1.19
Peer-review started: May 14, 2020
First decision: June 8, 2020
Revised: June 17, 2020
Accepted: June 19, 2020
Article in press: June 19, 2020
Published online: June 28, 2020
Lung cancer is the most common cause of cancer death in the world. Early diagnosis, screening and precise individualized treatment can significantly reduce the death rate of lung cancer. Artificial intelligence (AI) has been shown to be able to help clinicians make more accurate judgments and decisions in many ways. It has been involved in the screening of lung cancer, the judgment of benign and malignant degree of pulmonary nodules, the classification of histological cancer, the differentiation of histological subtypes, the identification of genomics, the judgment of the effectiveness of treatment and even the prognosis. AI has shown that it can be an excellent assistant for clinicians. This paper reviews the application of AI in the field of non-small cell lung cancer and describes the relevant progress. Although most of the studies to evaluate the clinical application of AI in non-small cell lung cancer have not been repeatable and generalizable, the research results highlight the efforts to promote the clinical application of AI technology and influence the future treatment direction.
Core tip: Artificial intelligence has been shown to help clinicians make more accurate judgments and decisions in non-small cell lung cancer screening and preliminary evaluation of lung nodules, histological differentiation and diagnosis, genomic identification, decision-making of therapy, prognosis of overall survival, metastasis or recurrence. Electronic medical records could be used as a source of artificial intelligence to help clinicians. This manuscript reviews the state of art artificial intelligence applications in clinical non-small cell lung cancer for those who will be interested in this field.